Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD

Current Alzheimer Research

Volumn 2, Issue 3, 2005, Pages 343-353

  Sparks, D Larry ^a,e   Sabbagh, Marwan N ^a   Connor, Donald J ^a   Lopez, Jean ^a   Launer, Lenore J ^b   Petanceska, Suzana ^c   Browne, Patrick ^d   Wassar, Dawn ^d   Johnson Traver, Sherry ^a   Lochhead, Jeff ^a   Ziolkowski, Chuck ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d Sun Health Boswell Hospital   (United States)

^e NONE   (United States)

Author keywords

Alzheimer's disease; Atorvastatin calcium; Clinical benefit; Treatment trial

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FREE RADICAL; GLUTATHIONE PEROXIDASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SUPEROXIDE DISMUTASE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ALZHEIMER DISEASE; BEHAVIOR DISORDER; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; OUTCOMES RESEARCH; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; STATISTICAL ANALYSIS;

ACTIVITIES OF DAILY LIVING; AGED; ALZHEIMER DISEASE; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; COGNITION; DEPRESSION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; FREE RADICALS; HEPTANOIC ACIDS; HUMANS; MALE; MENTAL STATUS SCHEDULE; PILOT PROJECTS; PYRROLES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 22144453835     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/1567205054367900     Document Type: Conference Paper

References (33)

1. Newell KL, Hyman BT, Growdon JH, Hedley-Whyte ET. Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer's disease. J Neuropathol Exp Neurol 1999;58(11):1147-1155.
2. Sparks DL, Hunsaker JC, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging 1990;11:601-607.
3. Sparks DL, Liu H, Scheff SW, Coyne CM, Hunsaker III JC. Temporal sequence of plaque formation in the cerebral cortex of nondemented individuals. J Neuropath Exp Neurol 1993;52:135-142.
4. Notkola I-L, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein Eepsilon4 allele, and Alzheimer's disease. Neuroepidemiol 1998;17:14-20.
5. Kivipelto M, Helkala E-L, Hallikainen M, et al. Elevated systolic blood pressure and high cholesterol levels at midlife are risk factors for late-life dementia. Neurobiol Aging 2000;21(1S):S174.
6. Sparks DL, Scheff SW, Hunsaker III JC, Liu H, Landers T, Gross DR. Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 1994;126:88-94.
7. Sparks DL. Intraneuronal β-amyloid immunoreactivity in the CNS. Neurobiol Aging 1996;17(2):291-299.
8. Sparks DL. Dietary cholesterol induces Alzheimer-like β-amyloid immunoreactivity in rabbit brain. Nutr Metab Cardiovasc Dis 1997;7(3):255-266.
9. Sparks DL. Differences and similarities in the pathogenesis of Alzheimer's disease and vascular dementia. Highlights:Postgraduate Dementia Course. Alzheimer's disease and vascular dementia and their interaction. Gothenburg, Sweden: Excerpta Medica Medical communications B. V., 1999: 1-36.
10. Poirier J. Etiological treatment of Alzheimer's disease. Highlights:Postgraduate Dementia Course. Alzheimer's disease and vascular dementia and their interaction. Gothenburg, Sweden: Excerpta Medica Medical communications B. V., 1999.
11. Rockwood K, Kirkland S, Hogan DB, et al. Use of Lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002;59:223-227.
12. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachmen DA. Statins and the risk of dementia. Lancet 2000;356:1627-1631.
13. Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2001;8(5):890-899.
14. Petanceska SS, DeRosa S, Olm V, et al. Statin therapy for Alzheimer's Disease. Will it work? J Mol Neurosci 2002;19:155-161.
15. Zandi P, Sparks DL, Khachaturian AS, et al. Do Statins Reduce Risk of Incident Dementia and AD? The Cache County Study. Arch Gen Psychiatry 2005;62:217-224.
16. Christ M, Bauersachs J, Liebetrau C, Heck M, Gunther A, Wehling M. Effects of atorvastatin treatment on sICAM-I and plasma citric oxide levels in hypercholesterolemic subjects. Clin Appl Thromb Hemost 2002;8:257-263.
17. Sanguigni V, Pignatelli P, Caccese D, et al. Increased superoxide anion production by platelets in hypercholesterolemic patients. Thromb Haemost 2002;87:796-801.
18. Maack C, Kartes T, Kilter H, et al. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 2003;108:1567-1574.
19. Franzoni F, Quinones-Galvan A, Regoli F, Ferriannini E, Galetta F. A comparative study of the in vitro antioxidant activity of statins. Int J Cardiol 2003;90:317-321.
20. McKhann G, Drachman D, Folstein M. Clinical diagnosis of Alzheimer's diseae. Neurology 1984;34:939-944.
21. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
22. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State;" A practical method for grading the mental state of patients for the clinician. J Psychiatric Res 1975;12:189-198.
23. Yesavage JA. Geriatric Depression Scale. Psychopharmacol Bull 1988;24(4):709-711.
24. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's Disease. Am J Psychiatry 1984;141:11-19.
25. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S22-S32.
26. Kaufer DI, Cummings JL, Cristine EL. Assessing the impact of neuropsychiatrie symptoms in Alzheimer's disease: The Neuropsychiatric Inventory Caregiver distress Scale. J Amer Geriatr Soc 1998;46:210-215.
27. Galasko D, Corey-Bloom J, Thal LJ. Monitoring progression in Alzheimer's disease. J Am Geriatr Soc 1991;39(9):932-941.
28. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S33-S39.
29. Beutler E. Red cell metabolism, a manual of biochemical methods. (3rd ed.) Orlando, FL: Grune & Strtton, 1984
30. Mathews PM, Jiang Y, Schmidt SD, Grbovic OM, Mercken M, Nixon RA. Calpain activity regulates the cell surface distribution of amyloid precursor protein. Inhibition of clapains enhances endosomal generation of beta-cleaved C-terminal APP fragments. J. Biol. Chem. 2002;Vol. 277(Issue 39):36415-36424.
31. Aisen PS, Schafer KA, Grundman M, et al. Effects of Rofecoxib or Naproxen vs placebo on Alzheimer disease progression. A randomized controlled trial. JAMA 2003;289:2819-2826.
32. Aisen P. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology 2002;58:1050-1054.
33. Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer's disease an Alzheimer's Disease Cooperative Study. Neurology 2000;54:588-593.